Keywords: ucb, presents, data, ph, iii, cimzia, trials

UCB presents data from two Ph III Cimzia trials

Article | 03 November 2008

Belgian drugmaker UCB presented results from two Phase III clinical trials evaluating its Cimzia (certolizumab pegol) PEGylated anti-Tumor Necrosis Factor ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

UCB

Go to company listing

Related Drugs

Certolizumab Pegol

Cimzia

methotrexate

Trexall

Go to drug listing